Aromatase inhibitor
Letrozole (Femara)
Letrozole (Femara) after one dose: 50% at ~42 h, 25% at 84 h, 12.5% at 126 h.
Drawn from the half-life in the app's model, ~42 h. The model's figures
- Compound
- Letrozole (Femara)
- Symbol
- LET
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Letrozole, sold as Femara, is a nonsteroidal competitive inhibitor of the aromatase enzyme system, and the US label states that it inhibits the conversion of androgens to estrogens.1 The US label's uses are all in postmenopausal women with breast cancer: adjuvant treatment of hormone receptor positive early breast cancer, extended adjuvant treatment after 5 years of tamoxifen, and treatment of advanced breast cancer.1 A 2026 trial report by Sun and colleagues in JAMA Network Open says aromatase inhibitors "have been widely used off-label in male infertility."4
The app's half-life of 42 hours sits beside a terminal elimination half-life of about 2 days on the US label and an apparent terminal elimination half-life in plasma of about 2 to 4 days in the UK summary of product characteristics.1,2 The app's oral bioavailability of 99% sits beside a mean absolute bioavailability of 99.9 ± 16.3% in 12 healthy postmenopausal women, reported by Sioufi and colleagues, whose affiliation is Laboratoires Ciba-Geigy, in 1997, and the UK summary of product characteristics gives 99.9%.5,2 The app's time to peak of about 8 hours sits beside a median tmax of 1 hour fasted and 2 hours fed in the UK summary of product characteristics.2 The app's typical dose of 0.25 to 2.5 mg a day sits beside the US label's dose of one 2.5 mg tablet once a day.1
The WADA 2026 Prohibited List names letrozole among aromatase inhibitors in class S4.1, and class S4 is prohibited at all times, in and out of competition.3
How it works
Sources in this part
In people
The US label states that letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.1 In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg suppressed plasma estradiol, estrone and estrone sulfate by 75% to 95% from baseline, with maximal suppression achieved within two-three days, according to the label.1 In 18 healthy men given single doses of CGS 20 267, which PubMed's record indexes under letrozole, estrone fell 60% to 85% from baseline at 24 hours at every dose from 0.02 mg to 30 mg, and estradiol fell by about 30% at 0.02 mg and by a maximum of about 90% at 30 mg.6
In animals
In adult female animals, the label states, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH and causing the regression of estrogen-dependent tumors.1
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~42 h
- Bioavailability
- 99%
- Typical dose
- 0.25–2.5 mg/day
- Route
- Oral
- Time to peak
- ~8 h
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~42 hours | The app's figure. The US label states about 2 days and the UK summary of product characteristics about 2 to 4 days.1,2 |
| Bioavailability (oral) | ~99% | Source figure: 99.9 ± 16.3% in 12 healthy postmenopausal women, and 99.9% in the UK summary of product characteristics. The US label states that letrozole is rapidly and completely absorbed.5,2,1 |
| Time to peak | ~8 hours | The app's figure. The UK summary of product characteristics gives a median tmax of 1 hour fasted and 2 hours fed, and states that food slightly decreases the rate of absorption but the extent (AUC) is not changed.2 |
| Route | Oral | A film-coated tablet containing 2.5 mg of letrozole.2 |
| Typical dose | 0.25 to 2.5 mg/day | The US label states one 2.5 mg tablet once a day, and 2.5 mg every other day for cirrhosis or severe hepatic impairment.1 |
| Steady state | 2 to 6 weeks1 | After daily 2.5 mg dosing. Steady-state concentrations are 1.5 to 2 times higher than predicted from a single dose per the US label, and approximately 7 times higher than after a single dose per the UK summary of product characteristics.1,2 |
| Distribution | About 1.9 L/kg | Volume of distribution, per the US label, which states that letrozole is weakly protein bound and that metabolism to an inactive carbinol metabolite excreted as a glucuronide is the major clearance pathway.1 |
The chart below draws the app's one-compartment model for letrozole, using the app's half-life of 42 hours and time to peak of about 8 hours. It is an illustration, not a measured level, and its 42-hour half-life is shorter than the label figures of about 2 days and about 2 to 4 days, so its curve falls faster.1,2 The interval choices follow the US label: once a day, and every other day for cirrhosis or severe hepatic impairment.1 Other combinations on the chart are arithmetic from the model and not a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Trunet and colleagues, 19936 | Open, dose-finding, single dose; CIBA-GEIGY authors, no sponsor stated in the source text | 18 healthy men, 9 dose levels and placebo, 3 men per dose | Single doses of 0.02 to 30 mg of CGS 20 267 | At 24 hours estrone fell 60% to 85% at every dose and estradiol by about 30% at 0.02 mg and about 90% at 30 mg; testosterone, LH and FSH rose dose-dependently; the authors reported good tolerability, and the record's index terms include "Headache chemically induced". |
| Thürlimann and colleagues, 2005 (BIG 1-98)7 | Randomised, phase 3, double-blind; the 2009 report states the trial was supported by Novartis8 | 8010 postmenopausal women with hormone-receptor-positive breast cancer | Groups assigned letrozole first against groups assigned tamoxifen first, sequential groups counted up to the switch; median follow-up 25.8 months | 351 against 428 events; hazard ratio 0.81 (95% CI 0.70 to 0.93; P=0.003); thromboembolism, endometrial cancer and vaginal bleeding more common with tamoxifen; skeletal and cardiac events and hypercholesterolemia more common with letrozole. |
| Mouridsen and colleagues, 2009 (BIG 1-98 update)8 | Randomised, phase 3, double-blind; supported by Novartis | 6182 women in the sequential comparison; 4922 in the monotherapy update | Letrozole 2.5 mg or tamoxifen 20 mg daily for 5 years, or 2 years of one then 3 of the other; median follow-up 71 months | Disease-free survival not significantly improved with either sequential treatment against letrozole alone (hazard ratios 1.05 and 0.96), with more early relapses on tamoxifen then letrozole than on letrozole alone; in the monotherapy update, median follow-up 76 months, 509 against 565 primary-end-point events for letrozole against tamoxifen (P=0.03); overall survival, letrozole against tamoxifen, hazard ratio 0.87 (95% CI 0.75 to 1.02; P=0.08). |
| Goss and colleagues, 2003 (MA-17)9 | Randomised, double-blind, placebo-controlled; US National Cancer Institute grants listed in the record | 5187 postmenopausal women who had completed 5 years of tamoxifen | Letrozole against placebo, planned 5 years; median follow-up 2.4 years | At the first interim analysis, 75 against 132 local or metastatic recurrences or new primary cancers in the contralateral breast; estimated 4-year disease-free survival 93% against 87% (P ≤ 0.001); deaths 31 against 42 (P=0.25); new osteoporosis diagnoses 5.8% against 4.5% (P=0.07); low-grade hot flashes, arthritis, arthralgia and myalgia more frequent with letrozole. |
| Legro and colleagues, 201410 | Randomised, double-blind, multicentre, against clomiphene; funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others | 750 women aged 18 to 40 with polycystic ovary syndrome | Letrozole 2.5 mg daily, rising after nonresponse to a maximum of 7.5 mg, or clomiphene 50 mg daily, for 5 days a cycle, up to 5 cycles | Live birth 103 of 374 (27.5%) against 72 of 376 (19.1%), P=0.007; 4 major congenital anomalies against 1 (P=0.65); pregnancy loss 31.8% against 29.1% (no significant difference); fatigue and dizziness more frequent with letrozole. |
| Sun and colleagues, 20264 | Randomised, multicentre, open-label, assessor-blinded; Chinese research grants, letrozole supplied by Jiangsu HengRui Medicine | 296 men with spermatogenic failure, 73.6% with nonobstructive azoospermia | Letrozole 2.5 mg daily plus vitamins C and E, or vitamins C and E alone, 3 months | Sperm concentration category upgrade in 21 of 147 (14.3%) against 8 of 149 (5.4%), risk difference 9.2% (95% CI 2.5% to 15.8%; P=.01); sperm concentration grade common odds ratio 2.65 (95% CI 1.28 to 5.47; P=.008); Dutch total motile sperm count category upgrade 6 of 147 (4.1%) against 1 of 149 (0.7%) (P=.03); no significant between-group differences in semen parameters; decreased libido 12.2% against 5.4% (P=.04). |
| Rasmussen and colleagues, 2025, as described by the Society for Endocrinology, 202611 | Randomised, placebo-controlled; terminated early because of poor recruitment | Symptomatic men with a history of non-medical androgen use and low serum testosterone; number not given in the statement | Letrozole or placebo; dose and length not given in the statement | Serum testosterone rose during treatment, the improvements were not sustained after withdrawal, and there were no clear improvements in sexual or depressive symptoms; the statement says the study was underpowered. |
Deeper analysis: BIG 1-98, letrozole against tamoxifen
BIG 1-98, reported by Thürlimann and colleagues in the New England Journal of Medicine in 2005 and updated by Mouridsen and colleagues in 2009, randomised postmenopausal women with hormone-receptor-positive breast cancer to letrozole, tamoxifen, or 2 years of one then 3 years of the other.7,8 At 5 years, estimated disease-free survival was 87.9% with letrozole alone, 87.6% with letrozole then tamoxifen, 86.2% with tamoxifen then letrozole and 84.6% with tamoxifen alone, of whom 612 of 1548 (39.5%) had crossed over to letrozole.8 In the updated monotherapy analysis, median follow-up 76 months, there were 509 primary-end-point events with letrozole against 565 with tamoxifen (P=0.03), and time to distant recurrence differed significantly in favour of letrozole (P=0.05).8 Five-year overall survival was 91.8% with letrozole and 90.9% with tamoxifen (hazard ratio 0.87; 95% CI 0.75 to 1.02; P=0.08), with 87 deaths without prior cancer events in each monotherapy group.8
Novartis, the manufacturer of letrozole, "distributed the study drugs and provided financial support but imposed no restrictions on the investigators with respect to trial data," according to the 2009 report.8 In that report Dr. Thürlimann disclosed owning stock in Novartis, Drs. Mouridsen and Smith consulting and lecture fees from Novartis, Dr. Mauriac consulting fees from Novartis and AstraZeneca and grant support from AstraZeneca, Dr. Forbes consulting fees from Eli Lilly, Novartis and AstraZeneca and lecture fees from AstraZeneca, and Dr. Goldhirsch consulting and lecture fees from Novartis, AstraZeneca and Pfizer.8 Novartis contracted with the study group that coordinated the trial for services related to its conduct and management, and the steering committee members who reviewed the article included a minority representation from Novartis.8 The authors wrote that "the limitations of the study include the selective crossover to letrozole among women assigned to tamoxifen monotherapy and the inability, after a median follow-up period of 6 years, to assess the influence of a potential carryover effect of letrozole on the results."8
Deeper analysis: MA-17, letrozole after tamoxifen
The MA-17 trial, reported by Goss and colleagues in the New England Journal of Medicine in 2003, was a double-blind, placebo-controlled trial of five years of letrozole in postmenopausal women with breast cancer who had completed five years of tamoxifen, with disease-free survival as the primary end point.9 After the first interim analysis the independent data and safety monitoring committee recommended termination of the trial, and the US label states that at unblinding less than 1% of patients had completed 5 years of follow-up.9,1
In the label's updated analysis at a median follow-up of 62 months, disease-free survival events were 344 (13.3%) against 402 (15.5%), hazard ratio 0.89 (95% CI 0.77 to 1.03; P=0.12), which the label says was heavily diluted by 60% of placebo patients switching to letrozole.1 The record for the 2003 paper lists US National Cancer Institute grants and does not carry the authors' disclosures or their own stated limitations.9
Deeper analysis: letrozole against clomiphene in polycystic ovary syndrome
The NICHD Reproductive Medicine Network trial, reported by Legro and colleagues in the New England Journal of Medicine in 2014, randomly assigned 750 women with polycystic ovary syndrome, defined by modified Rotterdam criteria, to letrozole or clomiphene for up to five cycles, and its primary outcome was live birth during the treatment period.10 Cumulative ovulation was 61.7% of treatment cycles with letrozole and 48.3% with clomiphene (P<0.001), twin pregnancy 3.4% against 7.4% (not a significant difference), fatigue 21.7% against 14.9%, dizziness 12.3% against 7.6% and hot flushes 20.3% against 33.0%.10
The trial was supported by grants from the NICHD, and the authors state that "neither manufacturer had a role in the study" and that the drugs were overencapsulated to look the same.10 Dr. Legro disclosed consulting fees from Ferring Pharmaceuticals, AstraZeneca and Euroscreen, Dr. Diamond consulting fees from EMD Serono and service on the board of directors of, and stock in, Advanced Reproductive Care, and Dr. Santoro grant support from Bayer and stock options in MenoGeniX.10 Among the authors' stated limitations are the relatively high dropout rate, an underpowered twin-pregnancy comparison (23% power), and four major congenital anomalies with letrozole against one with clomiphene, a difference that was not significant but, in their words, "given the group size, we cannot rule out a potential difference," they wrote.10 They also wrote that further study with larger numbers of infants is needed to clarify the safety and teratogenic risks of letrozole relative to other infertility therapies.10
Deeper analysis: letrozole in men with spermatogenic failure
Sun and colleagues, JAMA Network Open, 2026, ran a multicenter, open-label, assessor-blinded randomised trial at 10 male infertility centers in China from July 2023 to March 2024, in men aged 22 to 50 with spermatogenic failure, and the primary outcome was an upgrade of at least 1 WHO sperm concentration category at 3 months.4 Of 296 randomised men, 247 (83.4%) completed the trial and all 296 were in the primary analysis, with missing data counted as nonresponse.4
The authors write that men with nonobstructive azoospermia "demonstrated the lowest response rates" in the trial.4 Funding came from Chinese national, regional and foundation grants, Jiangsu HengRui Medicine Co Ltd provided letrozole, the funders had no role in the design and conduct of the study, and the authors report no conflicts of interest.4 The authors' limitations: "the open-label design may have introduced bias," the randomised phase "was limited to 3 months," and the trial "was conducted predominantly among Han Chinese men at academic centers, which may limit generalizability to other ethnic groups and clinical settings."4
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| US label, breast cancer1 | 2.5 mg tablet | Once a day | Median treatment duration 5 years in the adjuvant studies; optimal duration unknown |
| US label, cirrhosis or severe hepatic impairment1 | 2.5 mg | Every other day | Not stated |
| US label, hormone studies in postmenopausal patients with advanced breast cancer1 | 0.1 mg to 5 mg | Daily | Stimulation tests after 6 and 12 weeks of treatment |
| Trunet and colleagues, 19936 | 0.02 mg to 30 mg | Single administration | Single dose |
| Mouridsen and colleagues, 2009 (BIG 1-98)8 | 2.5 mg | Daily | 5 years, or 2 years followed by 3 years of tamoxifen |
| Legro and colleagues, 201410 | 2.5 mg, raised after nonresponse to a maximum of 7.5 mg | Daily for 5 days from cycle day 3 | Up to 5 menstrual cycles |
| Sun and colleagues, 20264 | 2.5 mg, plus vitamin C 100 mg and vitamin E 100 mg | Once daily | 3 months |
Side effects reported
Sources in this part
In the BIG 1-98 monotherapy arms (median treatment 60 months, median follow-up for safety 96 months), the US label lists adverse reactions of any grade in 2309 of 2448 patients (94.3%) on letrozole and 2212 of 2447 (90.4%) on tamoxifen, and grade 3 to 4 reactions in 26.0% and 24.8%.1 Hypercholesterolemia was reported in 52.3% on letrozole and 28.6% on tamoxifen, hot flashes in 33.5% and 38.0%, arthralgia or arthritis in 25.4% and 20.6%, vaginal bleeding in 5.3% and 13.1%, and, counted at any time after randomisation, bone fractures in 14.7% and 11.4% and endometrial hyperplasia or cancer in 0.4% and 2.9%.1 The US label's bone warning reports that at 24 months median lumbar spine bone mineral density fell 4.1% on letrozole and rose 0.3% on tamoxifen, and that in the MA-17B substudy median hip bone mineral density fell 3.8% on letrozole and 2.0% on placebo at 2 years.1 In MA-17 the 2003 report, a first interim analysis at a median follow-up of 2.4 years, lists low-grade hot flashes, arthritis, arthralgia and myalgia as more frequent with letrozole and vaginal bleeding as less frequent, with similar fracture rates.9 At a median follow-up of 62 months, the US label reports bone fractures at any time after randomisation in 13.3% on letrozole and 7.8% on placebo, and new osteoporosis in 14.5% and 7.8%.1
In the 3-month trial in men with spermatogenic failure, grade 1 proteinuria was the most common adverse event, in 21 of 147 (14.3%) on letrozole and 9 of 149 (6.0%) on control (P=.02), loss of libido occurred in 18 (12.2%) and 8 (5.4%) (P=.04), and aspartate aminotransferase increased in 17 (11.6%) and 9 (6.0%) (P=.09).4 Weight increased in 17 (11.6%) and 10 (6.7%) (P=.15) and alanine aminotransferase in 16 (10.9%) and 10 (6.7%) (P=.20), and scores on the MSF-4 sexual function questionnaire, on which higher scores indicate worse function, were worse with letrozole at 3 months (mean difference 2.7 points; 95% CI 1.9 to 3.5; P<.001).4 The authors note that the clinical significance of the low-grade proteinuria remains uncertain.4 The authors report that no treatment-related serious adverse events or deaths occurred.4 The US label states that Femara can cause fetal harm and is contraindicated for use in pregnant women, based on post-marketing reports, findings from animal studies and the mechanism of action.1 The post-marketing reports describe spontaneous abortions and congenital birth defects, and in rats and rabbits letrozole caused embryo-fetal toxicities at maternal exposures below the maximum recommended human dose.1 It also states that fatigue, dizziness and somnolence have been reported with the use of Femara.1
Bloodwork and markers
Sources in this part
In the men's trial at 3 months, median testosterone was 716.0 ng/dL with letrozole against 333.5 ng/dL with control (least-squares mean difference 350.1 from mixed-effects models for repeated measures; 95% CI 291.4 to 408.8), median estradiol 15.0 against 24.8 pg/mL, luteinizing hormone 17.9 against 7.5 mIU/L and follicle-stimulating hormone 35.0 against 17.0 mIU/L.4 The app lists total testosterone, free testosterone, estradiol, LH and FSH as markers to monitor, and the men's trial measured FSH, LH, testosterone, estradiol, prolactin, the testosterone to estradiol ratio and sex hormone-binding globulin.4
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List, in effect from 1 January 2026, lists aromatase inhibitors in S4.1, "including, but not limited to" anastrozole, exemestane, formestane, letrozole and testolactone, and states that prohibited substances in classes S4.1 and S4.2 are Specified Substances.3
The Society for Endocrinology's 2026 position statement on non-medical androgen use states that many men who discontinue, or cycle in and out of, non-medical androgen use self-administer so-called "post-cycle therapy," typically consisting of human chorionic gonadotrophin, selective oestrogen receptor modulators or aromatase inhibitors.11 It also states that existing evidence for such pharmacological interventions "remains limited and of low quality," with no robust evidence demonstrating improved long-term recovery or symptom outcomes.11
Storage and handling
Sources in this part
The US label states: store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).1
What is not known
Sources in this part
The US label states that in the adjuvant setting the optimal duration of treatment with letrozole is unknown, and that in the extended adjuvant setting the optimal treatment duration is not known.1 It states that safety and effectiveness in pediatric patients have not been established, and that differences in letrozole pharmacokinetics between adult and pediatric populations, and due to race, have not been studied.1
The authors of the men's trial state that the randomised phase was limited to 3 months and that long-term reproductive outcomes were not assessed.4 The Society for Endocrinology statement says there remains a lack of adequately powered, randomised, double-blind studies of pharmacological agents for sustained recovery after cessation of non-medical androgen use.11
Frequently asked questions
What is letrozole (Femara)?
What is the half-life of letrozole?
How long until letrozole peaks?
The UK summary of product characteristics gives a median tmax of 1 hour fasted and 2 hours fed.2 The Milligram app uses a time to peak of about 8 hours.
How long does letrozole take to reach steady state?
After daily 2.5 mg dosing, steady-state plasma concentration is reached in 2 to 6 weeks, according to the US label and the UK summary of product characteristics.1,2 Steady-state concentrations are 1.5 to 2 times higher than predicted from a single dose per the US label, and approximately 7 times higher than after a single dose per the UK summary of product characteristics.1,2
What is the bioavailability of oral letrozole?
How much does letrozole lower estradiol?
In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg suppressed plasma estradiol, estrone and estrone sulfate by 75% to 95% from baseline, according to the US label.1 In 18 healthy men given single doses of CGS 20 267 (3 men per dose; PubMed's record indexes it under letrozole), estradiol fell at 24 hours by about 30% from baseline at 0.02 mg and by a maximum of about 90% at 30 mg.6 In men with spermatogenic failure on 2.5 mg daily for 3 months, median estradiol was 15.0 pg/mL against 24.8 pg/mL with control.4
What side effects are reported with letrozole?
In the BIG 1-98 adjuvant study, the US label lists hypercholesterolemia in 52.3% on letrozole against 28.6% on tamoxifen, arthralgia or arthritis in 25.4% against 20.6%, and bone fractures, counted at any time after randomisation, in 14.7% against 11.4%.1 In the 3-month trial in men with spermatogenic failure, loss of libido occurred in 12.2% on letrozole and 5.4% on control, and grade 1 proteinuria in 14.3% and 6.0%.4 The US label states that Femara can cause fetal harm.1
Is letrozole banned by WADA?
Yes, the WADA 2026 Prohibited List names letrozole among aromatase inhibitors in class S4.1, which is prohibited at all times, in and out of competition.3
Guides, tools and comparisons
References
- Novartis Pharmaceuticals Corporation. FEMARA (letrozole) tablets, for oral use. US prescribing information, DailyMed, version 32, 15 June 2026. DailyMed label
- Novartis Pharmaceuticals UK Ltd. Femara 2.5 mg Tablets. Summary of Product Characteristics, electronic medicines compendium, revised 19 August 2025. UK SmPC
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In effect from 1 January 2026. WADA Prohibited List 2026
- Sun Y, et al. Letrozole and infertility among males with spermatogenic failure: a randomized clinical trial. JAMA Netw Open 2026. PMC13280704
- Sioufi A, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997. PMID 9429742
- Trunet PF, et al. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 1993. PMID 8345034
- Thürlimann B, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005. PMID 16382061
- Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009. PMC2921823
- Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003. PMID 14551341
- Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014. PMC4175743
- Grant B, et al. Management of non-medical androgen use: a position statement by the Society for Endocrinology. Endocr Connect 2026. PMC13641141